




- (51) International Patent Classification:
A61K 9/127 (2006.01)
- (21) International Application Number:
PCT/US2013/040325
- (22) International Filing Date:
9 May 2013 (09.05.2013)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
61/644,996 9 May 2012 (09.05.2012) US
- (71) Applicants: **WESTERN UNIVERSITY OF HEALTH SCIENCES** [US/US]; 309 E. Second Street, Pomona, CA 91766 (US). **TESORX PHARMA, LLC** [US/US]; 900 Willow Rd., Ste. B, Menlo Park, CA 94025 (US).
- (72) Inventors; and
- (71) Applicants (for US only): **BETAGERI, Guru, V.** [US/US]; 17325 Eastview Drive, Chino Hills, CA 91709 (US). **THIRUCOTE, Ramachandran** [US/US]; 397 Fletcher Drive, Atherton, CA 94027 (US). **KADAJJI, Veeran, Gowda** [IN/US]; 11030 Moorpark St, Apt. 18, North Hollywood, CA 91602 (US).
- (74) Agent: **LINDEMAN, Jeffrey, A.**; J.A. Lindeman & Co., PLLC, 3190 Fairview Park Drive, Suite 480, Falls Church, VA 22042 (US).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,

[Continued on next page]

(54) Title: PROLIPOSOMAL TESTOSTERONE FORMULATIONS



(57) Abstract: Novel testosterone formulations are disclosed where testosterone is incorporated into a phospholipid/cholesterol system to produce a proliposomal powder dispersion. The proliposomal powder dispersions of the invention may be formulated with pharmaceutically acceptable excipients to form pharmaceutical compositions. Enterically coated oral dosage forms are disclosed as are methods of treatment for testosterone replacement therapy.

FIG. 24



TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

(88) Date of publication of the international search report:

4 June 2015